Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.13B P/E - EPS this Y 87.50% Ern Qtrly Grth -
Income -481.45M Forward P/E -4,564.50 EPS next Y - 50D Avg Chg 2.00%
Sales 266.72M PEG - EPS past 5Y - 200D Avg Chg -12.00%
Dividend N/A Price/Book 30.70 EPS next 5Y - 52W High Chg -32.00%
Recommedations 2.00 Quick Ratio 2.31 Shares Outstanding 56.61M 52W Low Chg 42.00%
Insider Own 0.76% ROA -29.73% Shares Float 56.16M Beta 0.51
Inst Own 107.81% ROE -818.43% Shares Shorted/Prior 3.35M/3M Price 91.29
Gross Margin 83.36% Profit Margin -180.51% Avg. Volume 292,577 Target Price 0.28
Oper. Margin -26.59% Earnings Date Apr 25 Volume 199,786 Change -0.36%
About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S News
04/02/24 Biotech With 520% Sales Growth Nears Next Buy Point
03/22/24 Two Health Care Stocks Outperform S&P 500, Offer Entries
03/22/24 Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
03/22/24 Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
03/22/24 Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
07:50 AM 30 Biggest Biotechnology Companies in the World
03/11/24 The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
03/08/24 5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
03/07/24 Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
03/06/24 Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
03/04/24 Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
02/15/24 Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
02/15/24 Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
02/10/24 US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results
02/08/24 Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
02/07/24 Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
02/07/24 Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/06/24 Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
01/31/24 Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
01/31/24 Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
ASND Chatroom

User Image Night_Owl_Biotech Posted - 1 day ago

This morning $ITCI announced a Phase 3 win for its Caplyta (patented thru Dec. 2040) in MDD. Per ITCI, MDD is Caplyta's largest comm'l oppty. The attachment notes that ITCI trades at 32% of total 10-year analyst consensus revenue estimates. Highly respected peers were acquired for 32 to 38% of their respective total 10-year product revenue forecasts. $RETA was acquired at 48% of their management prepared 10-year revenue forecast. RETA may, again may, be the better peer as its product was approved 5 months before the acquisition was announced (if MDD is truly Caplyta's largest comm'l opportunity). We'd add Caplyta generics won't be available until 12/2040. Astra-Zeneca's Seroquel peaked @ $5.8B in FY11 sales before coming off patent as a mono-therapy, where Calyta is approved as a mono & a lithium adjunct (in bi-polar). Of course there are other considerations. We're only sharing this 1 analytic that may or may not be relevant. This is not investment advice. $AXSM $ASND

User Image opgenopgen Posted - 1 day ago

$ASND U.S. High Growth Tech and AI Stocks... https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/us?via=bullmarketstocks

User Image Thelonius_Stonk Posted - 03/26/24

$ASND looking good against the 50d

User Image Monkey_Banana_Genius Posted - 1 month ago

$ASND buyout? Long

User Image WallStJesus Posted - 1 month ago

$ASND UNUSUAL BULL SWEEPER

User Image Stock_Titan Posted - 1 month ago

$ASND Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 https://www.stocktitan.net/news/ASND/ascendis-pharma-to-participate-in-the-leerink-partners-global-gvraro1mixv8.html

User Image Barnman09 Posted - 02/29/24

$OPK Can anyone tell me how our competition $ASND has a mkt.cap of 8.5 billion and make less per quarter?? Give me a holiday! Opko should have a $20 to $40 SP. Way undervalued! $$$

User Image tymtested Posted - 02/28/24

$ASND looks like analysts pumping and somebody dumping.

User Image ElJoe Posted - 02/27/24

@CashMoneyBoy Luckily I sold more and invested elsewhere: $IMGN, $NKTX $ASND ....I did alright! Recognized 2 years ago this was a POS, and spent 2023 getting the fck out!

User Image techj2022 Posted - 02/25/24

$ASND like this commercial stage bio. big market for its lead drug. weekly candle is a beauty.

User Image Doozio Posted - 2 months ago

$ASND it shall in 🐒🍌🧠⏰

User Image Pika_Capital Posted - 2 months ago

$asnd something is cooking. Grew in top position at the moment

User Image tymtested Posted - 2 months ago

$ASND did somebody say games???

User Image AnaChart Posted - 2 months ago

$ASND https://anachart.com/wp-content/uploads/ana_temp/1707415313_soc-img.jpg

User Image tymtested Posted - 2 months ago

$ASND and this is a company with market cap of $8B??? Hhhhhmmmm…….

User Image epsguid Posted - 2 months ago

$ASND reported a loss of $1.66, consensus was ($2.15) via @eWhispers #epsbeat http://eps.sh/d/asnd

User Image Estimize Posted - 2 months ago

$ASND misses the Estimize EPS Consensus by 19c and beats the Estimize Revenue Consensus by $52.66M. Reports FQ4 earnings of $-1.65 EPS ... http://www.estimize.com/asnd/fq4-2023?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 2 months ago

$ASND Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results https://www.stocktitan.net/news/ASND/ascendis-pharma-reports-fourth-quarter-and-full-year-2023-u0miqwt0pkex.html

User Image Estimize Posted - 2 months ago

$ASND reports after the close, Estimize Consensus +0.50 EPS and -6.41M Revs compared to WS http://www.estimize.com/asnd/fq4-2023?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 2 months ago

$ASND Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/ASND/ascendis-pharma-to-participate-in-the-oppenheimer-34th-annual-mzkautnqvj8c.html

User Image tymtested Posted - 2 months ago

$ASND huge losses… stock going up… hhmmmmm

User Image StockInvest_us Posted - 2 months ago

Signal alert: $ASND - PivotPoint bottom https://stockinvest.us/l/YmrBz1DF7A

User Image Pika_Capital Posted - 2 months ago

$ASND beautiful action bulls, if there are any left lol

User Image FannyPackin Posted - 2 months ago

@AnchorsAweigh @Monkey_Banana_Genius @Doozio $ASND

User Image FannyPackin Posted - 2 months ago

$ASND sometimes I just shake my head when I sell puts instead of buying shares(like adbe at 320 last march and amd at 85).. 😅😅 this stock has been a beast..

User Image VirmoMopire Posted - 01/30/24

$ASND Keep an eye on this one. Could be something brewing. 🔍

User Image tymtested Posted - 01/18/24

$ASND are they selling any of the skytrofa?

User Image tymtested Posted - 3 months ago

$ASND certainly not fundamentals driving this stock

User Image UltraAlgo Posted - 3 months ago

$ASND Sell Rating from 9 signals, 15-min ticks 🚀 Chart by UltraAlgo https://i.redd.it/e4ampsjhavcc1.png

User Image tickeron Posted - 3 months ago

$ASND enters bullish trend https://srnk.us/go/4968103

Analyst Ratings
JP Morgan Overweight Apr 2, 24
Cantor Fitzgerald Overweight Apr 1, 24
Wells Fargo Overweight Mar 15, 24
Citigroup Buy Feb 8, 24
Wedbush Outperform Feb 8, 24
Cantor Fitzgerald Overweight Feb 6, 24
Cantor Fitzgerald Overweight Dec 20, 23
Wedbush Outperform Dec 20, 23
Jefferies Buy Dec 20, 23